Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Marrow Irradiation in Relapsed or Refractory Multiple Myeloma
NCT02043847Phase 1Completed
- Sponsor
- University of Illinois Chicago
- Start
- Jan 2014
- Primary completion
- Sep 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial in multiple myeloma (MM) (3 cohorts), sponsored by University of Illinois Chicago. Primary endpoint: Maximum Tolerated Dose (MTD) of Gy at 60 days. Started Jan 2014; status: completed.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02043847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043847.